Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neurofibroma

ClinicalTrials.gov lists 344 trials for Neurofibroma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 48.

MeSH D009455 Neoplasms Neoplasm C04 C10 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 52 Phase 1/2 Phase 1/2 30 Phase 2 Phase 2 105 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 15 Phase 4 Phase 4 3 Not applicable Not applicable 46 Observational Observational 83 Phase 1 Phase 1 52 Phase 1/2 Phase 1/2 30 Phase 2 Phase 2 105 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 15 Phase 4 Phase 4 3 Not applicable Not applicable 46 Observational Observational 83

Trials per phase (log scale)

1 more section with rows

31 of the 344 trials are tagged with Neurofibroma itself; the rest are tagged with a narrower condition beneath it.

Get the Neurofibroma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neurofibroma trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 23

1995: 1 trials (Phase 3 1) 1996: 1 trials (Phase 3 1) 1997: 1 trials (Phase 3 1) 1998: 2 trials (Phase 3 1, Phase 2 1) 1999: 2 trials (Phase 2 2) 2000: 4 trials (Observational 1, Phase 2 1, Phase 1/2 1, Phase 1 1) 2001: 7 trials (Observational 2, Phase 2 3, Phase 1 2) 2002: 5 trials (Observational 1, Not applicable 1, Phase 2 2, Phase 1 1) 2003: 3 trials (Phase 3 1, Phase 2 2) 2004: 7 trials (Observational 3, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1 1) 2005: 4 trials (Observational 1, Phase 2 3) 2006: 13 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2/3 2, Phase 2 4, Phase 1 1) 2007: 8 trials (Observational 3, Phase 3 1, Phase 2 4) 2008: 11 trials (Observational 3, Not applicable 1, Phase 2 3, Phase 1 4) 2009: 12 trials (Observational 1, Not applicable 2, Phase 2 4, Phase 1/2 1, Phase 1 4) 2010: 11 trials (Observational 4, Not applicable 1, Phase 2 2, Phase 1/2 2, Phase 1 2) 2011: 7 trials (Observational 1, Phase 2/3 1, Phase 2 2, Phase 1/2 2, Phase 1 1) 2012: 17 trials (Observational 6, Phase 2 7, Phase 1/2 1, Phase 1 3) 2013: 8 trials (Observational 1, Not applicable 3, Phase 2 1, Phase 1/2 2, Phase 1 1) 2014: 12 trials (Observational 2, Not applicable 2, Phase 2/3 2, Phase 2 5, Phase 1 1) 2015: 18 trials (Observational 6, Not applicable 2, Phase 3 1, Phase 2 3, Phase 1/2 3, Phase 1 3) 2016: 13 trials (Observational 4, Not applicable 2, Phase 2 7) 2017: 18 trials (Observational 5, Not applicable 2, Phase 2 9, Phase 1 2) 2018: 16 trials (Observational 3, Not applicable 4, Phase 4 1, Phase 3 1, Phase 2 5, Phase 1/2 1, Phase 1 1) 2019: 20 trials (Observational 6, Not applicable 5, Phase 4 1, Phase 2 6, Phase 1/2 1, Phase 1 1) 2020: 16 trials (Observational 1, Not applicable 3, Phase 3 2, Phase 2 4, Phase 1 6) 2021: 23 trials (Observational 7, Not applicable 2, Phase 3 1, Phase 2 5, Phase 1/2 3, Phase 1 5) 2022: 18 trials (Observational 5, Not applicable 4, Phase 2/3 1, Phase 1/2 3, Phase 1 5) 2023: 12 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2 3, Phase 1/2 2, Phase 1 1) 2024: 14 trials (Observational 4, Not applicable 2, Phase 2 5, Phase 1/2 2, Phase 1 1) 2025: 15 trials (Observational 3, Not applicable 2, Phase 2 5, Phase 1/2 2, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 17
2025 15
2024 14
2023 12
2022 18
2021 23
2020 16
2019 20
2018 16
2017 18

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 22 trials starting in 2026 and about 18 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 39 trials still running at the 2026-10-09 snapshot; registered median of 45 months across 209 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neurofibroma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 52
Phase 1/2 30
Phase 2 105
Phase 2/3 6
Phase 3 15
Phase 4 3
Not applicable 46
Observational 83
Expanded access 4

How many Neurofibroma trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 16
Recruiting 52
Enrolling by invitation 4
Active, not recruiting 32
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neurofibroma trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 48
AstraZeneca 14
European Organisation for Research and Treatment of Cancer - EORTC 13
Novartis Pharmaceuticals 6

Which drugs are being tested for Neurofibroma? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Selumetinib 23
EVEROLIMUS 8
Imatinib 7
GSK1120212 6
Lovastatin 5

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Doxorubicine 17
Ifosfamid 12
Radiation Therapy 7
Bevacizumab 1 6
Filgrastime (G-CSF) 4

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neurofibroma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Vomiting 58 16
Dyspnea 49 9
Pleural effusion 48 10
Dehydration 41 16
Febrile neutropenia 39 6

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neurofibroma? (22)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Imaging in gynecological disease (26): clinical and ultrasound characteristics of benign retroperitoneal pelvic peripheral-nerve-sheath tumors. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2023 Yes
Photodynamic Therapy for Benign Cutaneous Neurofibromas Using Aminolevulinic Acid Topical Application and 633 nm Red Light Illumination. Photobiomodulation, photomedicine, and laser surgery 2021 Yes
Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials. Neurology 2021 Yes
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro-oncology 2018 Yes
Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines. Journal of medical genetics 2016 Yes

Showing 5 of 22 publications.

Start your 14-day trial Email me all 22 publications as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Neurofibroma 252183 Exact Orphanet Rare Disease Ontology (ORDO)
Neurofibroma 252183 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence.

Browse all condition evidence pages